TRANSFORMATIVE 幸运168开奖飞艇中国体彩官网幸运飞艇五彩票类金刚官网.
Immunotherapy represents one of 全国统一飞艇记录官网+体彩网站极速赛车开奖, but off-target effects remain a challenge in the clinical setting.
Our technology is designed to unleash validated and proven proinflammatory mechanisms on tumors while preventing unwanted side effects on non-target tissue. We create systemically delivered targeted therapies that address the limitations of immuno-oncology.
Werewolf Therapeutics is a highly innovative company striving to redefine the cancer treatment landscape with potential best-in-class therapies.
Our technology is designed to unleash validated and proven proinflammatory mechanisms on tumors while preventing unwanted side effects on non-target tissue. We create systemically delivered targeted therapies that address the limitations of immuno-oncology.
Werewolf Therapeutics is a highly innovative company striving to redefine the cancer treatment landscape with potential best-in-class therapies.
OUR GOAL IS TO TRANSFORM THE LIVES OF CANCER PATIENTS
INNOVATIVE 幸运168开奖飞艇中国体彩官网实时同步速度
We are pioneering the development of 幸运飞艇记录官网+幸运5飞艇体彩号码 the body’s immune system for the treatment of cancer and other immune-mediated conditions.
These conditionally activated proinflammatory immune modulators, called INDUKINE™ And INDUCER™ molecules, are intended to remain inactive in peripheral tissue yet activate selectively in the tumor microenvironment.
Our team of experienced scientists invented our proprietary PREDATOR® protein engineering technology to design and engineer molecules that stimulate both adaptive and innate immunity with the goal of addressing the limitations of conventional proinflammatory immune therapies.
Join Our Team
金刚幸运5飞艇走势站+飞艇幸运查询体彩官网 Do you want to work at a company that embraces the same ideals? We’re looking for vibrant, creative, forward-thinking people to join our team. Click the link below and let us know that you’re interested. We’d love to talk to you.
金刚国际体彩赛车开奖结果查询网走势图工具
December 18, 2025
Werewolf Therapeutics Announces Pipeline and Business Updates
WATERTOWN, Mass., December 18, 2025 — Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”)...
Read More
November 7, 2025
Werewolf Therapeutics Presents Data Expanding Its PREDATOR® Platform at the Society for Immunotherapy of Cancer’s (SITC) 40th Annual Meeting
WATERTOWN, Mass., November 7, 2025 — Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”)...
Read More
November 4, 2025
Werewolf Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update
WATERTOWN, Mass., November 4, 2025 — Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”)...
Read More